Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iijima, N.
Right arrow Articles by Saito, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iijima, N.
Right arrow Articles by Saito, H.
Related Collections
Right arrow Neoplasia
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Functional Expression of Fas (CD95) in Acute Myeloid Leukemia Cells in the Context of CD34 and CD38 Expression: Possible Correlation With Sensitivity to Chemotherapy

Narikazu Iijima, Koichi Miyamura, Toshihide Itou, Mitsune Tanimoto, Ryou Sobue, and Hidehiko Saito

From the First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan; and the Department of Internal Medicine, Ichinomiya Hospital, Ichinomiya, Japan.

Clinical studies of bone marrow transplantation (BMT) suggest that the immune system contributes to the eradication of acute myeloid leukemia (AML). A recent study also showed that the Fas (CD95/APO1) mediates apoptotic signal from cytotoxic T lymphocytes. Sixty-four patients with AML were studied for the expression of Fas in the context of CD34 and CD38 coexpression. The clinical relevance of Fas expression and function on AML was also investigated. Fas was expressed on 2% to 98% of AML cells (2% to 20% in 11 patients, 20% to 50% in 20 patients, 50% to 80% in 24 patients, and 80% to 98% in nine patients). Only 44.4% of patients with AML M1 (French-American-British [FAB] classification) were Fas+ (>= 20% of leukemia cells expressed Fas), whereas 89.1% of patients with AML M2, M3, M4, M5 were Fas+ (P < .01). Among 43 CD34+ patients (>= 20% leukemia cells were CD34+), 34 were Fas+, and 19 of 21 CD34- patients were Fas+ (P = NS). Thirteen cases were studied for their expression of Fas in the context of CD34 and CD38 using three-color analysis. Fas is expressed at a high level in the gated CD34+CD38± and CD34+CD38+ population. In 10 AML samples, Fas was expressed at a higher level in CD34+/CD38+ population than in CD34+/CD38± or CD34- cell populations. Fas-induced apoptosis by anti-Fas monoclonal antibody (MoAb) was determined by morphologic features and colorimetric DNA fragmentation assay. Induction of apoptosis was found in 14 of 24 cases. However, no statistically significant correlation was observed between Fas expression and induction of apoptosis. Leukemia colony-forming unit assays suggested that in some cases, Fas-induced apoptosis occurred in the clonogenic cell populations. Parameters such as laboratory and clinical data at initial diagnosis were correlated with Fas expression and only response to initial induction chemotherapy showed significant correlation with Fas expression (P < .05). We conclude that the majority of AML cells exhibit variable expression of Fas, and apoptosis could be induced by anti-Fas MoAb in some cases. Our results suggest the Fas-mediated apoptosis may be clinically relevant, whereas the issue of clonogenic leukemia cells and Fas expression needs further studies.

Blood, Vol. 90 No. 12 (December 15), 1997: pp. 4901-4909
© 1997 by The American Society of Hematology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
haematolHome page
U. Testa and R. Riccioni
Deregulation of apoptosis in acute myeloid leukemia
Haematologica, January 1, 2007; 92(1): 81 - 94.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. H. Meyer, L. Karawajew, M. Schrappe, W.-D. Ludwig, K.-M. Debatin, and K. Stahnke
Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL
Blood, June 1, 2006; 107(11): 4524 - 4531.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. O. Iversen and H. Wiig
Tumor Necrosis Factor {alpha} and Adiponectin in Bone Marrow Interstitial Fluid from Patients with Acute Myeloid Leukemia Inhibit Normal Hematopoiesis
Clin. Cancer Res., October 1, 2005; 11(19): 6793 - 6799.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Tourneur, S. Delluc, V. Levy, F. Valensi, I. Radford-Weiss, O. Legrand, J. Vargaftig, C. Boix, E. A. Macintyre, B. Varet, et al.
Absence or Low Expression of Fas-Associated Protein with Death Domain in Acute Myeloid Leukemia Cells Predicts Resistance to Chemotherapy and Poor Outcome
Cancer Res., November 1, 2004; 64(21): 8101 - 8108.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Tamm, S. Richter, D. Oltersdorf, U. Creutzig, J. Harbott, F. Scholz, L. Karawajew, W.-D. Ludwig, and C. Wuchter
High Expression Levels of X-Linked Inhibitor of Apoptosis Protein and Survivin Correlate with Poor Overall Survival in Childhood de Novo Acute Myeloid Leukemia
Clin. Cancer Res., June 1, 2004; 10(11): 3737 - 3744.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Gajate, F. An, and F. Mollinedo
Rapid and Selective Apoptosis in Human Leukemic Cells Induced by Aplidine through a Fas/CD95- and Mitochondrial-mediated Mechanism
Clin. Cancer Res., April 1, 2003; 9(4): 1535 - 1545.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. de Thonel, A. Bettaieb, C. Jean, G. Laurent, and A. Quillet-Mary
Role of protein kinase C zeta isoform in Fas resistance of immature myeloid KG1a leukemic cells
Blood, December 15, 2001; 98(13): 3770 - 3777.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Laurent and J.-P. Jaffrezou
Signaling pathways activated by daunorubicin
Blood, August 15, 2001; 98(4): 913 - 924.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. T. Costello, F. Mallet, B. Gaugler, D. Sainty, C. Arnoulet, J.-A. Gastaut, and D. Olive
Human Acute Myeloid Leukemia CD34+/CD38- Progenitor Cells Have Decreased Sensitivity to Chemotherapy and Fas-induced Apoptosis, Reduced Immunogenicity, and Impaired Dendritic Cell Transformation Capacities
Cancer Res., August 1, 2000; 60(16): 4403 - 4411.
[Abstract] [Full Text]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020